Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Valneva ( (VALN) ) has issued an announcement.
On February 5, 2025, Valneva SE announced the UK marketing authorization for IXCHIQ®, the world’s first chikungunya vaccine, by the Medicines and Healthcare products Regulatory Agency (MHRA). This approval is based on successful Phase 3 data and marks the fourth global regulatory approval for the vaccine, following the US, Europe, and Canada. Valneva expects to expand access further with potential approvals in Brazil and other regions, and the vaccine is particularly significant given the recent chikungunya outbreak in India. The company has also partnered with CEPI and the Serum Institute of India to ensure affordable access to the vaccine in low- and middle-income countries.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes vaccines for infectious diseases, addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing vaccines from R&D to approvals, including the world’s first and only chikungunya vaccine.
YTD Price Performance: 18.86%
Average Trading Volume: 49,091
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $450.5M
Learn more about VALN stock on TipRanks’ Stock Analysis page.
